DIA456.09-0.70 -0.15%
SPX6,460.26-41.60 -0.64%
IXIC21,455.55-249.61 -1.15%

Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Benzinga·08/19/2025 10:21:33
Listen to the news

U.S. stock futures were mixed this morning, with the S&P 500 futures falling around 0.1% on Monday.

Shares of Fabrinet (NYSE:FN) fell sharply in pre-market trading following fourth-quarter results.

Fabrinet reported better-than-expected fourth-quarter financial results for fiscal 2025 on Monday. Fabrinet expects fiscal first-quarter revenue to be in the range of $910 million to $950 million, versus estimates of $916.72 million. The company expects first-quarter adjusted earnings to be in the range of $2.75 to $2.90 per share, versus estimates of $2.74 per share.

Fabrinet shares dipped 9.7% to $295.54 in the pre-market trading session.

Here are some other stocks moving lower in pre-market trading.

  • Xunlei Limited (NASDAQ:XNET) declined 8.4% to $8.05 in pre-market trading after jumping around 38% on Monday.
  • Precigen, Inc. (NASDAQ:PGEN) dipped 5.8% to $2.78 in pre-market trading. Precigen recently announced the FDA has approved PAPZIMEOS.
  • Adecoagro S.A. (NYSE:AGRO) fell 4.5% to $8.79 in pre-market trading after reporting downbeat quarterly results.
  • Immatics NV (NASDAQ:IMTX) shares fell 3.9% to $5.97 in pre-market trading.
  • Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) fell 3.9% to $38.51 in pre-market trading. On Friday, the U.S. Food and Drug Administration (FDA) approved Tonix Pharmaceuticals' Tonmya (cyclobenzaprine HCl sublingual tablets) for fibromyalgia in adults.

Now Read This:

Photo via Shutterstock

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2025 Webull Securities Limited. All rights reserved.